Law360, New York (July 31, 2006, 12:00 AM EDT) -- Looking to regulate the possible anti-competitive effects of deals that keep generic drug alternatives off the market, the Federal Trade Commission is investigating Mylan Laboratories Inc.’s patent litigation settlement related to the sleep-disorder drug modafinil.
Mylan revealed the probe in a quarterly report filed last Friday with the U.S. Securities and Exchange Commission, saying it was notified of the investigation in a July 11 letter sent by the FTC requesting “certain information.”
The company also stated that beginning in April 2006, it and four other drug...
FTC Probes Mylan Over Provigil Settlements
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
